NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
Clinical Trials
18 trialsNCT04162210 2026-02-11
DREAMM-3
GlaxoSmithKline
Phase 3 Active not recruiting
NCT05714839 2026-01-23
DREAMM-20
GlaxoSmithKline
Phase 1/2 Recruiting
NCT06679101 2026-01-08
DREAMM-10
GlaxoSmithKline
Phase 3 Recruiting
NCT02343042 2025-12-22
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Recruiting
NCT04398680 2025-12-04
DREAMM 13
GlaxoSmithKline
Phase 1 Withdrawn
NCT04091126 2025-11-28
DREAMM 9
GlaxoSmithKline
Phase 1 Active not recruiting
NCT07227311 2025-11-12
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT04126200 2025-11-06
DREAMM5
GlaxoSmithKline
Phase 2 Active not recruiting
NCT07217119 2025-10-15
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT05064358 2025-10-07
DREAMM 14
GlaxoSmithKline
Phase 2 Active not recruiting
NCT07150091 2025-09-02
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT07150104 2025-09-02
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT03828292 2025-08-19
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
GlaxoSmithKline
Phase 1 Completed
NCT07084896 2025-07-25
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT06956170 2025-06-11
DREAMM 8
GlaxoSmithKline
Phase 3 Active not recruiting
NCT04398745 2025-05-23
DREAMM12
GlaxoSmithKline
Phase 1 Active not recruiting
NCT06868667 2025-05-09
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting